Panel of Urinary Peptides Used to Diagnose Liver Fibrosis

A panel of 50 urinary peptides was shown to be a useful tool for the early diagnosis of liver fibrosis.

Liver fibrosis may result from infection by viruses such as hepatitis B and C, excessive alcohol consumption, a build-up of fat in the liver, or some autoimmune diseases. When the liver becomes fibrotic, accumulation of proteins causes the organ to shrink and become stiffer, which impedes its function. Peptide fragments of these proteins enter the bloodstream, where they are channeled into the kidneys and removed from the body via the urine.

Investigators at the University of Warwick (United Kingdom) and their colleagues sought to determine if these excreted peptides could be used to diagnose liver fibrosis in patients with chronic liver disease.

For this study, the investigators recruited 129 patients with varying degrees of liver fibrosis and 223 controls without liver fibrosis. Additionally, 41 patients with no liver, but kidney fibrosis were included to evaluate interference with expressions of kidney fibrosis. Urinary low molecular weight peptides were analyzed by capillary electrophoresis coupled to mass spectrometry.

Capillary electrophoresis coupled to mass spectrometry (CE-MS) has emerged in recent years as a hybrid technology using capillary electrophoresis (CE) instead of liquid chromatography for sensitive and high-resolution low molecular weight protein and peptide separation before mass spectrometry (MS). Notably, this method enables profiling urinary peptides in a mass range of 0.8 to 20 kilodalton (kDa).

Results revealed that CE-MS enabled identification of 50 urinary peptides associated with liver fibrosis. The peptides were sequenced and shown to be mainly fragments of collagen chains, uromodulin, and Na/K-transporting ATPase subunit gamma.

The investigators used this panel of 50 peptides to evaluate urine samples from a new group of patients. They reported correct identification of liver fibrosis patients in 84.2% of cases (sensitivity), and correct identification of those without fibrosis in 82.4% of cases (specificity).

Senior author Dr. Ramesh Arasaradnam, associate professor of gastroenterology at the University of Warwick Medical School, said, "Analyzing urine for the purposes of diagnostics is a promising research area, and this new study builds on existing work in my research group looking at urine peptides in colon cancer. While we are unlikely to see this in clinical practice for some time, it provides an avenue for further investigation that could help in the prevention of this terrible condition."

The liver fibrosis study was published in the November 5, 2020, online edition of the journal EbioMedicine.

Related Links:
University of Warwick